CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model

CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model

Abstract Background CD47/SIRPα axis is recognized as an innate immune checkpoint and emerging clinical data validate the interest of interrupting this pathway in cancer, particularly in hematological malignancies. In preclinical models, CD47/SIRPα blocking agents have been shown to mobilize phagocyt...

Full description

Bibliographic Details
Main Authors: Xavier Chauchet, Laura Cons, Laurence Chatel, Bruno Daubeuf, Gérard Didelot, Valéry Moine, Didier Chollet, Pauline Malinge, Guillemette Pontini, Krzysztof Masternak, Walter Ferlin, Vanessa Buatois, Limin Shang
Format: Article
Language:English
Published: BMC 2022-05-01
Series:Experimental Hematology & Oncology
Subjects:
Cancer immunotherapy
CD47
Bispecific antibody
B-cell lymphoma
Tumor microenvironment
Macrophages
Online Access:https://doi.org/10.1186/s40164-022-00279-w

Internet

https://doi.org/10.1186/s40164-022-00279-w

Similar Items